**7. Supplementary material**

**Supplementary Table 1.** Demographic and clinical factors evaluated in univariate analysis

ESRD, end-stage renal disease; FGF-23, fibroblast growth factor-23; HD, hemodialysis; iPTH, intact parathyroid hormone; PD, peritoneal dialysis

**Supplementary Table 2. Baseline patient demographics and clinical characteristics (supporting analysis set, N=569)**

\**p*<0.05. aWilcoxon rank sum test. bCochran–Mantel–Haenszel testing. cTime since ESRD is the difference between the date of ESRD diagnosis and the date of the screening visit. dTime since first dialysis is the difference between the date of the first dialysis and the date of screening visit for initial 24-week Phase 3 study.

In the supporting analysis set, sP-controlled were defined as patients for whom two-thirds of serum phosphorus readings taken between Week 12 and Week 52 were ≤5.5 mg/dL; sP-uncontrolled were defined as patients for whom two-thirds of serum phosphorus readings taken in the same time period were >6.0 mg/dL. CTx, carboxyterminal crosslinking telopeptide; ESRD, end-stage renal disease; HD, hemodialysis; PD, peritoneal dialysis; ROW, rest of the world; SD, standard deviation; sP, serum phosphorus; TRAP5b, tartrate-resistant acid phosphatase 5b.

**Supplementary Fig. 1. Mean (SD) and change from baseline in serum phosphorus levels in sP-controlled and sP-uncontrolled patients by treatment group over 1 year (main analysis set, n=497).**

\**p*<0.05, \*\**p*<0.01, \*\*\**p*<0.001 compared with sP-uncontrolled (baseline-adjusted ANOVA testing).

Values are mean ± SD.

sP-controlled were defined as patients who achieved a serum phosphorus level of ≤5.5 mg/dL at Week 52. ANOVA, analysis of variance; SD, standard deviation; sP, serum phosphorus.

**Supplementary Fig. 2. iPTH levels in sP-controlled and sP-uncontrolled patients by treatment group over 1 year (main analysis set).**

\*\**p*<0.01, \*\*\**p*<0.001 compared with sP-uncontrolled patients (baseline-adjusted ANOVA).

Values are mean ± standard deviation.

sP-controlled were defined as patients who achieved a serum phosphorus level of ≤5.5 mg/dL at Week 52. ANOVA, analysis of variance; iPTH, intact parathyroid hormone; SD, standard deviation; sP, serum phosphorus.

**Supplementary Fig. 3. FGF-23 levels in sP-controlled and sP-uncontrolled patients by treatment group over 1 year (main analysis set; N=497).**

\**p*<0.001 compared with sP-uncontrolled patients (baseline-adjusted generalized linear model on rank data).

Values are median (± 25th/75th percentiles).

sP-controlled were defined as patients who achieved a serum phosphorus level of ≤5.5 mg/dL at Week 52. ANOVA, analysis of variance; FGF-23, fibroblast growth factor-23; sP, serum phosphorus.